<DOC>
	<DOCNO>NCT00932802</DOCNO>
	<brief_summary>The observation period patient cover initial treatment period AveloxÂ® plus optional 2 long-term follow-up period ( 6 12 month ) .For patient , physician document data initial visit ( baseline ) least one short-term follow-up visit ( =initial treatment period ) .Optionally , long-term follow-up ( 6 12 month ) document , patient questionnaire fill .</brief_summary>
	<brief_title>Greatest International Antiinfective Trial With Avelox</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchial Diseases</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Outpatients diagnosis AECB decision take investigator prescribe moxifloxacin Exclusion criterion must read conjunction local product information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Non-Interventional</keyword>
	<keyword>Observational</keyword>
	<keyword>NIS</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>MXF</keyword>
	<keyword>Avelox</keyword>
	<keyword>AECB</keyword>
</DOC>